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Skin Barrier Disruption: A Requirement for Allergen
Sensitization?
Anna De Benedetto1, Akiharu Kubo2,3 and Lisa A. Beck1
For at least half a century, noninvasive techniques
have been available to quantify skin barrier function,
and these have shown that a number of human skin
conditions and disorders are associated with defects
in skin permeability. In the past decade, several genes
responsible for skin barrier defects observed in both
monogenetic and complex polygenic disorders have
been elucidated and functionally characterized. This
has led to an explosion of work in the past 6 years that
has identified pathways connecting epidermal barrier
disruption and antigen uptake, as well as the quality
and/or magnitude of the antigen-specific adaptive
immune response. This review will introduce the
notion that diseases arise from the dynamic crosstalk
that occurs between skin barrier and the immune
system using atopic dermatitis or eczema as the
disease prototype. Nevertheless, the concepts
put forth are highly relevant to a number of antigen-
driven disorders for which skin barrier is at least
transiently compromised, such as psoriasis, allergic
contact dermatitis, and blistering disorders.
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INTRODUCTION
The skin provides a vital barrier structure that protects
vertebrates from both routine and extreme environments
including exposure to antigens, solvents, UV light, deter-
gents, microorganisms, toxins, nanoparticles, and a variety of
physical insults (Elias and Feingold, 2006). In terrestrial
vertebrates, the epidermis, where most of the skin barrier
function resides, is highly stratified and has an outermost
layer that is cornified. Recent findings have shown that
epidermal barrier dysfunction is pathologically involved in a
variety of common, antigen-driven skin diseases, including
psoriasis (PS) and atopic dermatitis (AD). In this review, we
will briefly describe (1) the barrier system of the human
epidermis, (2) human disorders associated with skin barrier
defects and allergen sensitization, (3) murine studies that
have helped to clarify pathways connecting barrier and
immunity, and (4) epithelial-derived immune adjuvants
released in response to barrier disruption. We will focus on
immune recognition of allergens as a paradigm for all
incomplete and complete environmental and microbial
antigens. It is important to note that the skin microbiome,
which consists of both commensal and pathogenic bacteria,
affects the skin barrier and epithelial innate immune
responses. Consequently, skin microbes are thought to have
a critical role in the development of AD. These topics will
not be discussed further as they are reviewed in this 75th
Anniversary series (Nakatsuji and Gallo, 2011; Kong and
Segre, 2011).
Cutaneous allergen sensitization is a critical and early
event in the pathogenesis of AD, but this may also be true for
several other atopic disorders where defects in skin barrier
genes associate with diseases that manifest in other organs,
including food allergy, asthma, allergic rhinitis, and eosino-
phil esophagitis (Bremmer et al., 2008; Brown et al., 2008,
2011a; Weidinger et al., 2008; Blanchard et al., 2010). In
subjects with AD, the initial exposure to allergens (sensitiza-
tion phase) induces a systemic ‘‘allergic’’ T helper type 2
(Th2) cell response that is magnified with each subsequent
exposure (effector phase). Critical features of a Th2 immune
response include the local production of Th2 cytokines (IL-4,
IL-5, and IL-13), bone marrow production, prolonged survival
and activation of eosinophils and mast cells, and production
of allergen-specific IgE. For a long time, allergic diseases
were considered primarily immunological disorders. As a
consequence, research and drug development focused on
modifying the Th2 effector phase (Hanifin et al., 1985). Over
the past decade, there has been a shift in our thinking, with
the epithelium now recognized as a critical factor in the
development of allergic sensitization (Holgate, 2007; De
Benedetto et al., 2009; Bulek et al., 2010). In particular,
compelling data from human and mouse studies have
implicated skin barrier impairment as an indispensable event
in allergen sensitization (Palmer et al., 2006; Smith et al.,
2006; Cork et al., 2009; Fallon et al., 2009; Jin et al., 2009;
Oyoshi et al., 2009; O’Regan and Irvine, 2010; Spergel,
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2010). The specific pathways connecting epidermal barrier
disruption to allergen sensitization are beginning to be
elucidated. The overriding hypothesis is that epidermal
disruption would allow skin-resident antigen-presenting cells
such as Langerhans cells (LCs; epidermis) or dendritic cells
(DCs; dermis) to capture environmental antigens (Kubo et al.,
2009; Figures 1 and 2). In addition, barrier-disrupted
keratinocytes would release immune adjuvants that activate
and mature LCs/DCs, as well as affect their ability to direct
naive Th cell polarization and thereby affect the character of
the Th response (Figure 3). Whether the adaptive immune
response that ensues can feedback and affect barrier function
has not been fully explored (Figure 3). In this review, we will
summarize the evidence for and possible mechanism(s)
involved in the induction of allergen sensitization in the
context of skin barrier defects.
OVERVIEW OF THE EPIDERMAL BARRIER
Stratum corneum—the proverbial ‘‘moat’’ that is the
preliminary defense for the ‘‘castle’’
The horny layer of the epidermis was initially considered
to be a loose collection of amorphous keratin filaments
separated by wide empty spaces (Rothman, 1954). The
‘‘basket-weave’’ appearance of this layer, as it is observed in
formalin-fixed specimens, has long misled histopathologists.
Kligman and Christophers demonstrated that this appearance
was an artifact of sample preparation. They were the first to
recognize its cellular nature, coining the term ‘‘corneocytes’’
(Christophers and Kligman, 1964b; Kligman, 2006, 2011).
Corneocytes were noted to appear as disk-shaped cells with a
polygonal outline (Goldschmidt and Kligman, 1967), and the
sodium hydroxide immersion technique demonstrated that
the stratum corneum (SC) wasB15 cells thick in adult human
skin samples from most body sites (Christophers and Kligman,
1964a). This same technique also demonstrated that corneo-
cytes are encased by well-defined ‘‘cornified envelopes,’’
which have been extensively studied since then (Eckert et al.,
1993; Madison, 2003; Candi et al., 2005; Proksch et al.,
2008). At first, the intercorneocyte space seemed empty as
viewed by electron microscopy. This turned out to be an
artifact of fixation and sample processing. Ruthenium
tetroxide fixation and staining demonstrated that the inter-
cellular spaces were filled with stacks of lamellar structures,
which are now recognized as multiple stripes of hydro-
phobic and hydrophilic structures formed by various inter-
cellular lipids (Elias, 2005). These intercellular spaces also
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Figure 1. Tight junction (TJ) penetration of Langerhans cell (LC) dendrites. (a, c) Layers of the stratum granulosum (SG) are designated SG1, SG2, and SG3,
counting from the skin surface inward. In murine epidermis, TJs are found in the intercellular spaces between SG2 cells. Blue dotted lines represent TJs. (b, d)
Activated LCs (i.e., major histocompatibility complex (MHC) class II positive) elongate their dendrites to dock with and penetrate epidermal TJs. (a) Zonula
occludens-1 (ZO-1) and claudin-1 accumulate at penetration points (yellow arrows), where novel tricellular TJs are formed between LC dendrites and
surrounding keratinocytes to prevent significant barrier disturbance. (b) Rotated views of an activated LC dendrite are shown. EZ-link sulfo-NHS-LC-biotin
was applied topically on mouse skin. Trace amounts of this biotin tracer are observed in LC dendrites that have crossed the TJ barrier (arrowheads; upper b).
The images were originally published in the Journal of Experimental Medicine (Kubo et al., 2009).
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include various proteases that control desquamation and
processing of antimicrobial peptides that act as a microbial
barrier and control the growth of both commensal and
pathogenic bacteria (Braff et al., 2005).
Studies demonstrating enhanced skin permeability after SC
removal highlight the importance of the SC as a barrier
structure (Monash, 1957; Malkinson, 1958; Blank and Gould,
1959). However, it is not clear whether several or all of these
approaches to disrupt the SC may also disrupt the tight
junctions (TJs) found immediately below the SC. Dr Elias and
his colleagues have published a large number of studies
characterizing the SC components responsible for barrier
function and how they are altered in normal and pathologic
conditions (reviewed in Elias, 1981, 2005; Elias and Feingold,
2006). It was initially proposed by Scheuplein in 1971 that
exogenous substances transited through the SC by direct
transmembrane diffusion (Scheuplein and Blank, 1971).
Later, it became clear that the intercorneocyte space
provided the pathway through which exogenous, more
lipophilic substances pass to reach the sub-SC layers of the
epidermis. The surface proteins of the ‘‘cornified envelope’’
were shown to be tightly bound to hydroxyl-acylsphingosine
molecules, which suggests that each corneocyte envelope
has its own lipid envelope providing a barrier against the
passage of water and water-soluble substances (Swartzen-
druber et al., 1987). Various physical and chemical penetra-
tion enhancers including exposure to water alone were
shown to have the ability to disrupt the intercellular
multilaminar membranes, creating openings within the
intercellular spaces called ‘‘lacunae,’’ through which hydro-
philic and hydrophobic substances could penetrate (Menon
and Elias, 1997; Warner et al., 1999).
The TJ barrier: the proverbial ‘‘portcullis’’ that is the final
defense for the ‘‘castle’’
In the 1940s, Dr Rothman first suggested that another barrier
structure in the skin controlled diffusion of water and solutes
through the paracellular pathway (Rothman and Flesch,
1944). In his words, ‘‘The impermeability of the skin to
water and electrolytes is caused neither by the presence of a
greasy-waxy cover of the skin nor by the presence of the
horny layer. The seat of the absorption barrier is to be placed
in the transitional layers between cornified and noncornified
epithelium, ie, in the stratum granulosum (SG)y’’ (Rothman
and Flesch, 1944). This absorption barrier is called TJ and is
the only barrier structure in monolayered or simple epithelia
demarcating the body surface of urochordates, but has also
been recognized more recently in the stratified epithelia of
vertebrate skin. Thus, TJs are an ancient barrier system of the
body surface, which have been conserved from urochordates
and fish that lack SC to mammals. Although Hashimoto had
described the appearance of TJ structures in the granular layer
of human epidermis in 1971 (Hashimoto, 1971), this barrier
has long been overlooked or ignored in mammalian skin. The
importance of this barrier structure in mammalian epidermis
was revived by identification of claudins as integral
transmembrane proteins found in all TJs. The profound
epidermal permeability abnormalities observed in claudin-1
Inside=
dermis
Skin
barriers 
Antigens Langerhans cells
Outside=
environment
TJ
SC
Figure 2. The epidermis has two formidable barrier structures that are analogous to a castle’s moat (stratum corneum (SC); blue water) and portcullis
(tight junction (TJ); white gate). Epicutaneous sensitization requires that the antigen be engulfed by an antigen-presenting cell such as an epidermal dendritic
cell or Langerhans cell (LC). (a) Under resting conditions, the immune system does not respond to environmental factors such as allergens. (b) When the
SC is breached (i.e., drawbridge is down), allergens may cross the moat, but will still be blocked by an intact TJ barrier (portcullis). LC dendrites are found
below TJ (i.e., behind the portcullis). (c) When the portcullis is opened (TJ loosened), LC dendrites extend through these weakened TJs and take up allergens
and initiate an adaptive immune response. In addition, it is hypothesized that small allergens may penetrate leaky TJs and be taken up by LC/DC whose
dendrites are below the TJs. It is not clear whether a transient break in both epidermal barriers (SC and TJ) is required for LC dendrites to penetrate TJs.
This dual barrier system uniquely found in the skin may explain why we do not respond to a myriad of antigens that reach our skin surface daily and
consequently why our skin is usually uninflammed.
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knockout mice and claudin-6 transgenic mice solidified the
importance of this second skin barrier structure (Furuse et al.,
2002; Turksen and Troy, 2002). TJs seal the intercellular
spaces between SG keratinocytes (Furuse et al., 2002; Kubo
et al., 2009). TJs are not just physical barriers, they also
exhibit ion and size selectivity. Their barrier function varies
significantly in ‘‘tightness’’ depending on cell type and
physiological requirements, enabling dynamic regulation of
substances that traffic between extra-TJ and inside-TJ
compartments including dendritic processes from antigen-
presenting cells (Tsukita and Furuse, 2002; Kubo et al., 2009;
Figures 1 and 2).
SKIN BARRIER DEFECTS PROMOTE ALLERGEN
SENSITIZATION: EVIDENCE BASED ON HUMAN
DISEASES
Disorders characterized by enhanced desquamation:
Netherton’s syndrome and peeling skin syndrome, type B
The association of skin barrier defects with allergic manifes-
tations has been demonstrated in two genodermatoses that
are disorders of desquamation, namely Netherton’s syndrome
(Online Mendelian Inheritance in Man (OMIM) 256500) and
peeling skin syndrome, type B (OMIM 270300; Table 1). Both
diseases are characterized by superficial intraepidermal
detachment and atopic diathesis. In the SC, the corneocytes
are tightly bound together via corneodesmosomes, the end
product of epidermal desmosomes modified by the incor-
poration of corneodesmosin (CDSN). In the desquamation
process, kallikrein (KLK)-related peptidases such as KLK5 and
KLK7 degrade CDSN and induce cleavage of corneodesmo-
somes, resulting in detachment of corneocytes (Ovaere et al.,
2009). The protease activity of KLKs is inhibited by LEKTI
(lymphoepithelial Kazal-type-related inhibitor), encoded by
the serine protease inhibitor, Kazal type 5 (SPINK5) gene.
Loss-of-function mutations in SPINK5 (chromosome 5q32)
leading to accelerated desquamation is the defect in
Netherton’s syndrome, a severe autosomal recessive ichthyo-
tic condition characterized by a chronic AD–like condition,
allergen sensitization, and other atopic disorders such as
asthma and allergic rhinitis (Frenk and Mevorah, 1972).
Interestingly, coding polymorphisms in the SPINK5 gene
have been found in association with AD and disease
severity (Walley et al., 2001; Cork et al., 2009), and more
recently with food allergy in children with AD (Kusunoki
et al., 2005). Although Hubiche et al. (2007) did not
find an association in a French AD population, they did
observe an association between the E420K polymorphism
and serum IgE levels, suggesting that this barrier defect
predisposes subjects to a Th2 response to environmental
allergens.
Recently, two distinct mutations in the CDSN gene
(chromosome 6p21) have been shown to be associated with
peeling skin syndrome, type B (Israeli et al., 2011), an
autosomal recessive ichthyosiform erythroderma character-
ized by peeling of the skin and allergen sensitization (Oji
et al., 2010; Israeli et al., 2011). Patients with peeling
skin syndrome, type B have been reported to have high serum
IgE levels, eosinophilia, and food allergies (Oji et al., 2010).
In summary, defects in two different proteins that result in
enhanced SC desquamation are strongly associated with a
Th2 adaptive immune response to environmental allergens
as noted by elevated IgE levels and peripheral eosinophilia
and clinical manifestations of an atopic disease(s). It is
important to note that the CDSN gene is located in PSORS1,
one of the major PS susceptibility loci, and polymorphisms in
this gene have been associated with PS in some populations
(Jenisch et al., 1999; Capon et al., 2004; Helms et al., 2005).
As PS is a disease of delayed desquamation, it is assumed
that the CDSN mutations observed in PS would likely inhibit
their degradation by KLKs and therefore would not likely
explain the barrier defect of PS subjects.
Disorder of disturbed lipid metabolism: ichthyosis prematurity
syndrome
Ichthyosis prematurity syndrome (OMIM 608649, chromo-
some 9q34) is a rare syndrome characterized by the clinical
triad of premature birth, thick caseous desquamating
epidermis, and neonatal asphyxia (Niemi et al., 1993). The
diagnosis is often made by characteristic ultrastructural
findings demonstrating conspicuous membrane inclusions
in the SC, and most cases are associated with mutations in a
gene encoding for the FATP4 (fatty acid transport protein 4;
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Figure 3. Epidermal barrier function and immune responses are tightly
linked. Primary barrier defects lead to the release of a number of epidermal-
derived mediators including ones that are considered pro-Th2 and pro-Th17.
Some of these cytokines are released in an autocrine manner through
proteinase-activated receptor (PAR)-2 activation or by epithelial-derived
‘‘danger signals’’ that act on innate immune receptors expressed on
keratinocytes. The presumption is that barrier disruption comes in different
flavors, each resulting in a specific adjuvant profile that would either favor a
Th2, Th17, or another adaptive immune response to an antigen. Several Th2
and Th17 products establish an autocrine feedback loop and further aggravate
barrier disruption (e.g., secondary barrier defects). To date, this has been best
characterized for Th2 cytokines (Howell et al., 2007; Sehra et al., 2010).
Ag, antigen; LC, Langerhans cell; TGF-b, transforming growth factor-b;
Th, T helper; TLR2, Toll-like receptor 2; TSLP, thymic stromal lymphopoietin.
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Klar et al., 2009; Sobol et al., 2011). The FATP4 protein has a
central role in the transport and activation of fatty acids in the
endoplasmic reticulum of keratinocytes and is thought to be
important in the maintenance of normal epidermal barrier
function (Milger et al., 2006). Patients with this condition can
have peripheral eosinophilia, an AD-like condition, an
extensive keratosis pilaris-like condition, and a family history
of atopic disorders (Bygum et al., 2008). Although the clinical
features of the few subjects reported in the literature to
date are incomplete, there is still a suggestion that a SC lipid
defect, which causes a barrier phenotype in genetically
altered mice (Moulson et al., 2007), is associated with
markers of systemic Th2 polarity (e.g., eosinophilia) and
atopy (Table 1).
Disorders characterized by reduced expression of a key SC
structural protein—ichthyosis vulgaris and AD
Filaggrin (FLG) is expressed in SG layers as a 4400-kDa
precursor protein called profilaggrin. Profilaggrin is dephos-
phorylated and cleaved by proteases into FLG monomers,
with keratin-binding activities that are thought to contribute
to the cell compaction observed in the lower SC (Dale et al.,
1978). FLG monomers are further degraded into ‘‘natural
moisturizing factors’’ that maintain hydration of the upper SC
(Scott and Harding, 1986; Rawlings and Matts, 2005;
Sandilands et al., 2009) and also have anti-staphylococcal
properties in vitro (Miajlovic et al., 2010). Mutations in the
FLG gene were identified initially as the cause of ich-
thyosis vulgaris (IV; OMIM 146700; chromosome 1q21) and
Table 1. Epidermal barrier defects and allergen sensitization in human diseases
Human disease Barrier-related defects Local immune phenotype
Atopy/Th2 immune
response
Reference
(PMID)
Desquamation abnormalities
Netherton’s syndrome k SPINK5;m activity of proteases
(ELA2 and KLKs 5, 7, and 14);
abnormal FLG processing and
lipid lamellae
m TSLP Association with atopic
disorders and m IgE
10835624
19414552
20179351
Peeling skin syndrome,
type B
k CDSN ND Association with atopic
disorders, m IgE, and m EOS
21191406
20691404
Disturbed lipid metabolism
Ichthyosis prematurity
syndrome
k FATP4; membrane inclusions
in SC
ND Association with AD-like
condition, m EOS
19119129
Abnormalities in structural proteins
Ichthyosis vulgaris k Or absent FLG ND Association with atopic
disorders, mIgE
16550169
18159904
Atopic dermatitis Dysregulated EDC (including
k FLG); k proteases inhibitors
and m proteases; lipid
abnormalities; TJ abnormalities,
k CLDN1 and 23, m Cx26
m Pro-Th2 cytokines (e.g., TSLP,
IL-25, IL-33); Th2, Th22, and
Th17 (only in acute lesions);
Th2 and Th1 in chronic lesions
Association with atopic
disorders, m IgE, and
m EOS
16550169
18396323
19494826
21163515
21388665
21419481
Psoriasis Dysregulated EDC Th1 and Th17 Rarely observed modest
m IgE
18432274
21388665
21419481
Epidermis blistering disorders
Bullous pemphigoid Subepidermal blisters Th2 cytokines, tissue eosinophils
(early lesions)
m IgE and m EOS 6345605
9452886
12783647
Pemphigus vulgaris Suprabasilar acantholysis Th2 cytokines, tissue eosinophils
(early lesions)
m IgE 4217592
20015693
11161984
Epidermolysis bullosa
pruriginosa
Anchoring fibril abnormalities,
mutation in COL7A1
ND m IgE 16965364
Abbreviations: AD, atopic dermatitis; CDSN, corneodesmosin; CLDN, claudin; COL7A1, collagen, type VII, a-1; Cx26, connexin 26; EDC, epidermal
differentiation complex; ELA2, elastase 2; EOS, eosinophilia; FATP4, fatty acid transport protein 4; FLG, filaggrin; KLK, kallikrein; ND, not determined;
PMID, PubMed identifier or PubMed unique identifier; SPINK5, serine peptidase inhibitor Kazal type 5; SC, stratum corneum; Th, T helper; TJ, tight junction;
TSLP, thymic stromal lymphopoietin.
www.jidonline.org 953
A De Benedetto et al.
Skin Barrier and Allergen Sensitization
subsequently as a major predisposing factor for AD (Table 1;
Palmer et al., 2006; Smith et al., 2006). To date, the strong
association of FLG mutations with AD is one of the most
robust genotype–phenotype linkages observed in human
complex genetic disorders (van den Oord and Sheikh,
2009). Several case–control studies have also demonstrated
a strong association between FLG mutations and early AD
onset, disease severity, eczema herpeticum, AD-related
asthma, and greater allergen sensitization (Weidinger et al.,
2006; Gao et al., 2009; Schuttelaar et al., 2009; van den
Oord and Sheikh, 2009). Interestingly, several studies have
shown that FLG mutations confer a substantial risk for other
atopic disorders recognized as Th2-polarized diseases includ-
ing allergic rhinitis, IgE-mediated peanut allergy, and
eosinophilic esophagitis. These associations were observed
even after controlling for coexistent AD (Weidinger et al.,
2008; Blanchard et al., 2010; Brown et al., 2011b). This is
difficult to understand, as FLG immunostaining is restricted to
the cornified epithelium of the skin, oral mucosa, and nasal
vestibule, with no detectable staining observed in epithelium
from bronchial biopsies, as well as gastrointestinal epithelium
(Ying et al., 2006; De Benedetto et al., 2008; Weidinger
et al., 2008). Therefore, FLG mutations are unlikely to affect
barrier function and allergen sensitization in the organs
where these diseases manifest. One interpretation of these
findings is that FLG mutations may drive disease at distant
mucosal sites by enabling allergen sensitization through a
defective skin (and/or oral) barrier, whereas subsequent
allergen responsiveness occurs in these other epithelial beds
(e.g., upper airway or gastrointestinal tract). This model
seems feasible, as we know that not all subjects with FLG
mutations develop AD. For example, the carrier frequency is
as high as 12% in healthy Northern European controls,
suggesting that these mutations by themselves may not be
sufficient to induce AD and/or a Th2 adaptive immune
response. In addition, the model presupposes that subjects
with allergic rhinitis and food allergy likely have a barrier
defect in the relevant epithelial surface that may be either
genetic or acquired to explain their organ-specific disease
manifestations. In the case of allergic rhinitis, the barrier
defect may occur in the context of a viral upper respiratory
infection, which often proceeds an exacerbation of the
disease, and in the case of food allergy one could argue that
the infants and young children who develop this allergic
disease have a delay in the normal intestinal barrier
maturation that occurs shortly after birth.
Between 37 and 70% of IV patients present with atopic
conditions, most commonly AD, but also allergic rhinitis and
asthma (Wells, 1966; Bremmer et al., 2008; Brown et al.,
2008). Interestingly, some IV subjects have allergic rhinitis
and high IgE levels without concomitant AD, providing
further support for the notion that FLG mutations simply
confer a risk for allergen sensitization through the skin (Oji
et al., 2009). Somewhat surprisingly, a small German IV
cohort study found no difference in the prevalence of atopic
disorders based on FLG genotype (e.g., one or double
mutation; Oji et al., 2009). They also evaluated the number
of epidermal dendritic cells identified by CD1a staining, as a
marker of early immunological activity, based on previous
work demonstrating that subjects with more severe AD had
increased epidermal DCs (Novak et al., 2004). They observed
increased epidermal CD1aþ cells only in the atopic IV
subgroups, which was independent of FLG genotype,
suggesting that cutaneous reactivity in these subjects was
not determined by the presence or absence of FLG expres-
sion. Collectively, clinical assessments of AD and IV subjects
suggest that FLG mutations predispose subjects to allergen
sensitization but that these mutations are not sufficient, as
other genetic and environmental influences are likely
promoting the Th2 immune response observed in susceptible
individuals. One speculation is that other epidermal barrier
defects might also contribute to and/or modulate the
epicutaneous sensitization and ultimately the allergic pheno-
type. Table 1 highlights several human skin diseases that are
thought to have a barrier defect and summarizes what we
know about their local and systemic adaptive immune
responses.
It is well known that the magnitude of the barrier defect in
AD, as measured by transepidermal water loss (TEWL) at
nonlesional sites, correlates with disease severity and serum
IgE (Lee et al., 2006; Gupta et al., 2008; Hon et al., 2008).
Using this physiological measure of epidermal barrier
function, Boralevi et al. (2008) demonstrated that AD infants
with two or more positive allergen patch tests had higher
TEWL than infants with one or no positive tests. Further
studies are needed to clarify the relationship between
physiological measures of barrier health and integrity (e.g.,
TEWL, surface pH, SC hydration, SC cohesion, lipid
composition of SC, and barrier recovery) and allergen
sensitization in human subjects. Surprisingly, the biochem-
ical basis for elevated TEWL is still not known. The literature
suggests that nonlesional TEWL abnormalities are not
explained by FLG mutations (Hubiche et al., 2007; Nemo-
to-Hasebe et al., 2009; Jungersted et al., 2010; O’Regan
et al., 2010). However, Flohr et al. (2010) showed that FLG
mutations were associated with higher TEWL in clinically
normal-appearing forearms in a small cohort of 3-month-old
infants, which was not dependent on AD status. Collectively,
these studies suggest that FLG mutations may have a minor
role in the TEWL abnormalities observed in AD subjects, but
they are certainly not the entire story.
Nevertheless FLG genotypes do seem to have a role in a
number of other physiological measures of barrier function
including skin hydration (Scott and Harding, 1986; Kezic
et al., 2008), surface pH, SC cohesion, and paracellular
permeability of SC with the water-soluble tracer, lanthanum
(Krien and Kermici, 2000; Fluhr et al., 2010; Gruber et al.,
2011). AD subjects have a number of barrier abnormalities in
addition to increased TEWL, including increased surface pH,
reduced SC hydration, and enhanced barrier recovery. As we
discover the biochemical basis for these abnormalities, we
will be able to address how each of them interact in a
bidirectional way with the immune system (Figure 3).
We have recently demonstrated that AD subjects have a
defect in TJ, as noted by a remarkable impairment of
bioelectric properties of their ex vivo epidermis, and this
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may be due to reduced expression of the TJ components,
claudins 1 and 23 (De Benedetto et al., 2011). Claudin-1
levels were inversely correlated with Th2 biomarkers (IgE and
eosinophilia), suggesting that reductions in this TJ protein
may affect the systemic immune phenotype or vice versa (De
Benedetto et al., 2011). This introduces the notion that AD
subjects may have defects in both barrier structures, SC and
TJs, and the relative contribution of each may contribute to
the heterogeneity characteristic of this disease (e.g., disease
onset, natural history, magnitude of allergen sensitization,
and comorbid atopic conditions). Recent studies of skin
biopsies from FLG heterozygous and homozygous IV subjects
have demonstrated a FLG gene dose-dependent inhibition in
TJ protein expression, suggesting that there is a dynamic
interaction between these two epidermal barrier structures,
SC and TJs (Gruber et al., 2011). Whether these changes
affect TJ function is still not known. Developing a better
understanding of how these two key epidermal barrier
structures interact will likely yield information that will have
broader implications than just inflammatory skin disorders. In
summary, these studies suggest that damage to both epi-
dermal barriers (SC and TJ) might promote the elongation of
LC dendrites through TJ barrier and consequently their uptake
of allergens/antigens from the skin surface (Figures 2 and 3).
It is interesting to note that several autoimmune disorders
and genodermatoses that result in full epidermal detachment
are characterized by Th2 inflammation. For example, in the
autoimmune blistering disorders (bullous pemphigoid, herpes
gestationis and pemphigus vulgaris) there is a clear Th2
response, which is observed early in the disease. It is unclear
whether the adaptive response occurs before the full
thickness epithelial disruption or as a consequence of it
(Arbesman et al., 1974; Bushkell and Jordon, 1983; De Pita
et al., 1997; Borrego et al., 1999; Feliciani et al., 1999; Fabbri
et al., 2003; Nagel et al., 2010; Table 1). Similarly, in the
genodermatosis epidermolysis bullosa pruriginosa (OMIM
60412) (Yamasaki et al., 1997; Mellerio et al., 1999), a skin
fragility disorder caused by mutations in the COL7A1 gene,
and characterized by anchoring fibril abnormalities and
sublamina densa blistering, the patients have been reported
to have high serum IgE and eosinophilia (McGrath et al.,
1994; Table 1). The complete repertoire of IgE antigen
specificity is unclear even in bullous pemphigoid, herpes
gestationis, and pemphigus vulgaris, where BP180, BP230, or
desmoglein 3 account for only part of the serum IgE measured
in these patients. The assumption is that these patients have
IgE reactivity to other antigens, and the specificity of these
responses would be interesting to characterize further. One is
left wondering whether the profound barrier disruption
characteristic of these disorders promotes the production of
epithelial-derived Th2 adjuvants (e.g., thymic stromal lym-
phopoietin (TSLP), IL-33, IL-25, and so on).
SKIN BARRIER DEFECTS PROMOTE ALLERGEN
SENSITIZATION—WHAT HAVE MURINE MODELS
TAUGHT US?
There are a remarkable number of mouse models for which
a barrier defect phenotype has been observed (Table 2).
We have chosen a few examples to highlight the complexity
inherent to epidermal barrier integrity. We have highlighted
genetically altered mice that denote the import of both SC
and TJ structural proteins, as well as components of other
intercellular junctions such as adherens and gap junctions,
transcription factors, nuclear receptors, proteases/antipro-
teases, and proteins relevant for lipid metabolism (Table 2).
Studies such as these will continue to inform us about the
complex network required to form both skin barrier structures
(SC and TJ) under both homeostatic and inflammatory
conditions.
How epidermal barrier defects affect the adaptive immune
response to an antigen has been studied by a number of
groups (Wang et al., 1996; Kondo et al., 1998; Spergel et al.,
1998; Herrick et al., 2000; Strid et al., 2004, 2006; Oyoshi
et al., 2009). These studies have demonstrated that epicuta-
neous sensitization with a protein allergen elicits a local and
systemic Th2-predominant response, as noted by increases of
IL-4, IL-5, and antigen-specific IgE and IgG1, but low or
absent induction of IFN-g and IgG2a, in the skin and draining
lymph nodes in both C57BL6 and BALB/c mouse strains that
are, at baseline, thought to be inherently Th1 and Th2 prone,
respectively (Kondo et al., 1998; Spergel et al., 1998; Herrick
et al., 2003). Importantly, in all studies, the Th2-biased
immune response was achieved only after a number of
barrier-disrupting methods were used, including shaving,
repeated tape stripping, and prolonged (X4 days) and often
repeated patch application(s) with an occlusive dressing that
would result in maceration and thereby lead to barrier
disruption. At least one group has shown that the magnitude
of the Th2 response, as measured by IL-4 expression in tissue
and draining lymph nodes (Kondo et al., 1998), was
enhanced by the degree of skin barrier disruption. Interest-
ingly, IFN-g levels (e.g., Th1 response) did not change with
variation in barrier disruption (Kondo et al., 1998). No studies
have evaluated IL-17 levels as a marker of a Th17 response
under similar experimental conditions of graded barrier
disruption.
Tissue neutrophilia and the local expression of IL-17,
IL-17A, both markers of a Th17 adaptive immune response,
have been observed in IL-4, IL-13, and dual-knockout mice or
in mice that are deficient in the transcription factor STAT6
(signal transducer and activator of transcription 6), which is
critical for the differentiation of Th2 effector cells (Herrick
et al., 2003; He et al., 2007). This work, combined with
in vitro studies suggesting that Th2 cytokines may reduce
expression and biological functions of Th17 cytokines (Eye-
rich et al., 2009; Nograles et al., 2010), suggests that these
two Th phenotypes counteract each other. This is in keeping
with findings in humans where there is a remarkable paucity
of tissue neutrophils in AD skin biopsies, despite modest
expression of prototypic Th17 cytokines, suggesting that
Th2 inflammation dampens the functional Th17 response
(Nograles et al., 2009; Suarez-Farinas et al., 2011; Guttman-
Yassky et al., 2011a, b). This is in sharp contrast with PS, a
prototypic Th17/Th1 skin disease, characterized by tissue
neutrophilia and relative paucity of Th2 cytokines, for which
the antigens and conditions under which sensitization occurs
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remain a mystery (Guttman-Yassky et al., 2008; Koga et al.,
2008).
These murine models of epicutaneous allergen challenge
induce skin lesions that are similar to AD (Spergel et al.,
1998). The sensitized mice have increased scratching
behavior, thickened epidermis, inflammatory infiltration of
CD4þ T cells and eosinophils, expression of Th2 cytokines,
with modest increases in IFN-g, Th2 chemokines such as
eotaxin and the Th2 adjuvant, TSLP, as well as allergen-
specific IgE (Kondo et al., 1998; Spergel et al., 1998; Herrick
et al., 2003). In addition, these mice developed airway
hyperresponsiveness to methacholine and eosinophilia after a
single dose of inhaled ovalbumin. This demonstrates that
antigen education epicutaneously on barrier-disrupted skin is
Table 2. Overview of transgenic mouse models characterized by epidermal barrier defects and atopy
Mouse model Barrier-related defects Barrier effects
Atopy/Th2 immune
response
Reference
(PMID)
Cornified envelope/SC
SPINK5R820X/R820X Absence of LEKTI;
m FLG monomers
Detachment of SC; dehydration ND; m TSLP;
early death
15590704
LOR/ Absence of L-granule E Percutaneous dye penetration
(outside-in barrier) after E17.5; E TEWL
ND 11038185
Intercellular junctions
CLDN1/ k CLDN1 m TEWL; m biotin permeability
(inside-out barrier)
ND 11889141
(k14-cre)E-cadherinFl Abnormal TJ; k CLDN1 m TEWL; E percutaneous dye penetration
(outside-in barrier); m biotin permeability
(inside-out barrier)
ND 15775979
Inv-CLDN6-tg m CLDN6; k CLDN1 and
abnormal differentiation
ND, lethal ND 17914196
Inv-DSG3-tg Thin SC with a compact lamellar
pattern; loss of corneocyte
adhesion
m TEWL ND 11309406
Inv-Cx26-tg m Cx26 m TEWL; m percutaneous dye
penetration (outside-in barrier)
ND 16628254
Transcription factors
(k14-cre)IKK1EKO k CLDN23; k OCLD; m DSG3;
lipid abnormalities in SC
m TEWL; m percutaneous dye
penetration (outside-in barrier)
ND 17351639
p63 Null k CLDN1; SC abnormality m TEWL ND 18648642
RARa mutant Absence of multilamellar structure m TEWL ND 7867929
Spontaneous dermatitis
NC/Nga (ARC) Unknown; spontaneous dermatitis
at week 8
m TEWL After EC 11167677
Flaky tail (ft/ma) Lack FLG; unknown matted
phenotype
E Basal TEWL After EC 11121144
Flaky tail (ft/ft) Lack FLG E Basal TEWL After EC 19349982
Miscellaneous
Epidermal IL-4-tg Spontaneous dermatitis ND m IgE; asthma 11676841
APOC1+/+ Lipid abnormalities m TEWL m IgE 18049452
ADAM10/ Reduction of SS m TEWL m TSLP 21205794
Abbreviations: ADAM, a disintegrin and metalloprotease; APOC1, apolipoprotein C1; ARC, air-regulated condition; CLDN, claudin; Cx26, connexin 26;
DSG, desmoglin; EC, epicutaneous allergen sensitization; FLG, filaggrin; IKK1, I-k-B kinase 1; Inv, involucrin; LEKTI, lymphoepithelial Kazal-type-related
inhibitor; LOR, loricrin; ND, not determined; OCLD, occludin; PMID, PubMed identifier or PubMed unique identifier; RAR, retinoic acid receptor;
SC, stratum corneum; SPINK5, serine peptidase inhibitor Kazal type 5; SS, spinous layers; TEWL, transepidermal water loss; tg, transgenic; TJ, tight junction;
TSLP, thymic stromal lymphopoietin; E, no difference.
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sufficient to elicit systemic Th2 allergic inflammation in a
distant organ such as the lower airways and esophagus
following relevant challenge (e.g., inhaled vs. oral, respec-
tively; Spergel et al., 1998; Strid et al., 2005; Akei et al.,
2006). This may help explain the so-called ‘‘allergic march’’
where AD is the earliest atopic disorder to present, followed,
not infrequently, by the development of other atopic diseases
such as allergic rhinitis, asthma, and food allergy. In addition,
it highlights the importance of cutaneous allergen sensitiza-
tion even if the ultimate allergen elicitation occurs in a distant
organ.
To demonstrate the importance of the route of immuniza-
tion (e.g., sensitization phase), Strid et al. (2004) evaluated
whether the immunological response differed if the allergen
(e.g., peanut protein) was applied on disrupted epidermis
(24 hours after tape stripping) or injected subcutaneously with
complete Freund’s adjuvant. They found that the epicuta-
neous route generated a Th2 immune response in draining
lymph nodes and spleen (higher IL-4 and antigen-specific IgE
and lower IFN-g, IL-10, and IgG2a) in contrast with the
subcutaneous route, which induced a Th1 immune response
(high IFN-g and IgG2a and low IL-4 and antigen-specific IgE).
This is not too surprising as complete Freund’s adjuvant is a
Th1 and possibly Th17 adjuvant commonly used in many
vaccines. A more interesting comparison would be to
evaluate the adaptive immune response to subcutaneous
administration of the antigen with a Th2 adjuvant. In
subsequent work, this group demonstrated that immunization
with an antigen applied on barrier-disrupted epidermis was
able to switch an established Th1 response to a Th2 response
(Strid et al., 2006). Interestingly, the prevention of the Th1
immune response was specific to the antigen applied on the
skin, as exposure to a different antigen was still able to induce
a Th1 response in the same animal. Collectively, this work
suggests that epidermal barrier disruption can be a ‘‘real-life’’
Th2 adjuvant.
A reductionist approach to barrier disruption is necessary
to delineate the importance of specific barrier defects and
their relevance to the immunological abnormalities observed
in AD. Fallon et al. (2009) have done just that by identifying
the FLGmutation present in the spontaneous recessive mouse
mutant referred to as flaky tale (ft) mouse. To eliminate the
unknown effect of the matted mutation, Fallon et al. (2009)
backcrossed the flaky tail mouse onto the C57BL/6 strain
(Presland et al., 2000; Fallon et al., 2009). They (Fallon et al.,
2009) found that C57BL/6 ft/ft homozygotes generated
allergen-specific IgE (as well as IgG2a and IgG1) and a
mixed Th1 (IFN-g), Th2 (IL-5, IL-4, and IL-13), and Th17
(IL-17) response after epicutaneous allergen challenge as
compared with heterozygotes (ft/wt) or wild-type (wt/wt)
mice. In this study, the epicutaneous sensitization was
elicited with relatively little barrier disruption (shaving and
allergen application for 5 days 3 cycles), and with this
protocol the C57BL/6 ft/wt and wt/wt had no inflammation
compared with saline-challenged sites. In other words, this
sensitization protocol was not sufficient to induce a Th2
response in the C57BL/6 mouse strain, which Herrick et al.
(2000) have shown is possible with sufficient barrier
disruption. Oyoshi et al. (2009), using the naturally occurring
flaky tail mouse (with the matted mutation) and a similar
epicutaneous allergen sensitization protocol, found an
enhanced Th17 (IL-17A and IL-23) with similar Th2 (IL-4 and
IL-13) and Th1 (IFN-g) response compared with wild-type
strain controls (BALB/c and C56BL/6). Collectively, this work
highlights the permissive nature of the FLG knockout mouse
for epicutaneous sensitization and demonstrates the promis-
cuous nature of the adaptive immune response, which does
not favor a specific Th profile. In the study of Fallon et al.
(2009), although baseline TEWL was not different among the
three groups (ft/ft, ft/wt, and wt/wt), there was a substantial
increase in TEWL observed only in the ft/ft after allergen
sensitization that was commensurate with the cellular
infiltrate, suggesting that it was the result of an inside-out
mechanism. Last, although human studies have shown that
FLG mutations predispose AD subjects to the development of
asthma (van den Oord and Sheikh, 2009), epicutaneous
sensitization in the ft/ft mouse model did not evoke an
effector response in the airway as has been seen in other
barrier-disrupted, epicutaneous allergen challenge models
(Herrick et al., 2000; Spergel et al., 1998). It is worth
mentioning that the allergen sensitization and AD-like pheno-
type was only observed in ft/ft and not in heterozygous (ft/wt)
animals, whereas the majority of FLG-associated AD cases
have a single FLG mutated allele (e.g., are heterozygotes). The
authors suggested that the lack of lung sensitization in this
model could reflect the use of the C57BL/6 strain, which is less
susceptible to allergen-induced Th2 inflammation as compared
with BALB/c. Alternatively, the lack of lung reactivity may also
suggest that additional skin barrier defects need to be present at
the site of allergen sensitization, and these may prove to be
more critical determinants of the Th2 response characteristi-
cally observed in AD.
One caveat to consider when comparing antigen
challenge models is that the purity of the antigen preparation
is a critical determinant of the immunological outcome. For
example, many allergen preparations are contaminated with
ligands that can trigger innate immune receptors (e.g.,
lipopolysaccharides or peptidoglycans) and therefore would
have an adjuvant effect. Even more confusing is the growing
literature suggesting that many allergens themselves activate
innate immune receptors (e.g., house dust mite activating
dectin-1 and Toll-like receptor 4 (TLR4); ragweed activating
TLR4; nickel activating TLR4; cockroach activating TLR2;
Page et al., 2008; Trompette et al., 2009; Schmidt et al.,
2010; Li et al., 2011). Several other variables that may be
equally important include the dose of antigen used, age and
sex of mice, dressing used to apply antigen to the skin
surface, anatomic site where sensitization occurs, ‘‘cleanli-
ness’’ of the vivarium (e.g., determinants of microbial skin
flora), and type and magnitude of barrier disruption used
(Kondo et al., 1998; Spergel et al., 1998; Strid et al., 2004;
Oyoshi et al., 2009).
In summary, murine studies strongly suggest that skin
barrier disruption either by physical means or by targeted
gene deletion, as in the FLG/mouse, significantly
enhances immunological responses to the epicutaneous
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application of allergens. Similarly, the mode of barrier
disruption may determine the flavor of the immune response,
with some favoring Th2 and others favoring a Th17 response.
A better understanding of the epithelial factors that regulate
effector T-cell maturation and polarization at the skin surface
is crucial for the development of preventive and therapeutic
strategies in antigen-driven skin disorders such as AD, PS,
and allergic contact dermatitis.
POTENTIAL MECHANISMS FOR A TH2 RESPONSE
FOLLOWING EPIDERMAL BARRIER DISRUPTION
The first step in the development of any adaptive immune
response is the activation of innate immune receptors or
pattern-recognition receptors by highly conserved pathogen-
associated molecular patterns common to many classes of
pathogens or danger-associated molecular patterns, which
are cellular components released in the context of cell
damage/necrosis (Janeway and Medzhitov, 2002). Pattern-
recognition receptor activation results in the production of
specific mediators (cytokines, chemokines, and antimicrobial
peptides) as well as the activation and recruitment of immune
cells (immature DCs, natural killer cells, and neutrophils;
De Benedetto et al., 2009). Th2 responses are commonly
elicited by extracellular parasites or environmental allergens
(Finkelman and Urban, 1992; Paul and Zhu, 2010) and are
mediated in part by the actions of a number of Th2-promoting
cytokines including TSLP, IL-33 and IL-25 that are produced
by tissue-resident cells. In contrast, Th17-promoting cyto-
kines include IL-1b, IL-6, IL-23, and transforming growth
factor-b (Wilson et al., 2007; Hammerich et al., 2011). The
specific innate immune pathways that mediate the effector
T-cell phenotype are not fully characterized (Paul and Zhu,
2010).
Immune mediators released after epidermal barrier disruption
In 1994, Nickoloff and Naidu (1994) were the first to
demonstrate the epidermal expression of several inflamma-
tory cytokines (tumor necrosis factor-a, CXCL8/IL8, IL-10,
IFN-g, and transforming growth factor-a) and the Th17-
promoting cytokine, transforming growth factor-b, following
tape stripping of normal human skin. More recently, several
groups have extended and confirmed these findings, showing
enhanced epidermal mRNA expression of Th2 promoting
cytokines (e.g., TSLP and IL33) as well as TNFa, heat shock
protein (Hsp) 90, Hsp70, and CXCL8 after tape stripping of
healthy subjects (Angelova-Fischer et al., 2010; Dickel et al.,
2010). Importantly, this work introduced the notion that
endogenous danger-associated molecular patterns or alar-
mins, such as Hsp70, Hsp90, and IL-33, could activate innate
receptors following epidermal injury.
TSLP is an IL-7-like cytokine that was originally character-
ized for its role in T- and B-cell development, but more recent
literature strongly implicates its role in Th2 cell differentiation
and, in particular, in the pathogenesis of allergic inflamma-
tion (Ziegler and Artis, 2010). In 2002, Soumelis et al. (2002
demonstrated that TSLP was highly expressed in the
epidermis from AD subjects and that TSLP-activated DCs
produced Th2-attracting chemokines (TARC and MDC) and
primed naive T cells to differentiate into Th2 cells. Impor-
tantly, TSLP was not detected in the skin from nickel-induced
allergic contact dermatitis or systemic lupus erythematosus
(Soumelis et al., 2002). Increased serum TSLP is an indicator
of epidermal barrier dysfunction in two mouse models with
epidermal barrier defects, namely mice with a loss of
NOTCH signaling and those with a defect in FATP4 (Demehri
et al., 2008). Epithelium that is deficient in LEKT1, the
protease inhibitor mutated in Netherton’s syndrome, ex-
presses more TSLP, which is mediated by the enhanced
activity of KLK5 in a proteinase-activated receptor-2–depen-
dent manner (Briot et al., 2009, 2010). This finding links a
genetic barrier defect (e.g., mutation in SPINK5) that leads to
overactivity of serine proteases to TSLP expression and has
important implications for the pathogenesis of AD. In vitro
studies have demonstrated that a number of proteases can
act through proteinase-activated receptor-2 and induce TSLP
expression from keratinocytes or airway epithelial cells
(Kouzaki et al., 2009; Zhang et al., 2009). Interestingly, a
number of allergens, including house dust mite, cockroach,
fungi, and several pollens, contain proteases that may also
trigger epithelial production of TSLP through a similar
mechanism (Takai and Ikeda, 2011). This may also be true
for Staphylococcus aureus, which produces extracellular
proteases and chronically colonizes the skin surface of most
AD patients (Takai and Ikeda, 2011). Proteases may also
disrupt epithelial TJs, either by direct actions on TJ proteins or
by activation of proteinase-activated receptor-2 (Wan et al.,
1999; Tai et al., 2006; Runswick et al., 2007; Takai and
Ikeda, 2011). In summary, protease-mediated barrier disrup-
tion might have dual actions on the epithelium. They may
induce the production of the Th2-promoting cytokine, TSLP,
and also facilitate allergen uptake by LCs by disrupting TJs. It
is intriguing to speculate that the more immunodominant
allergens (e.g., house dust mite allergens) might be the ones
that can both disrupt skin barriers and directly or indirectly
act as Th2 adjuvants.
Epithelial TSLP is also induced through a TLR2-, TLR3-,
and TLR5-mediated mechanism in response to microbial pro-
ducts (Kinoshita et al., 2009; Ma et al., 2009; Le et al., 2010;
Vu et al., 2010), as well as in response to ragweed allergen,
which is a TLR4-mediated event (Li et al., 2011). In a human
skin injury model, the epidermal TSLP immunostaining was
observed primarily at later time points (e.g., 48 hours) after
the skin barrier perturbation (Angelova-Fischer et al., 2010).
This delayed expression of TSLP suggests that TSLP may not
be as critical in the sensitization phase as in the elicitation
phase of an AD lesion. Therefore, Th2 adjuvants that are
induced rapidly would be more likely candidates to initiate a
Th2 immune response in the context of barrier disruption.
In contrast, IL-33, a novel member of the IL-1 family, is
rapidly released in response to tissue injury and is a more
likely candidate to initiate Th2 polarization during the
elicitation phase. IL-33 was identified in 2005 using a
computational database approach to search for the ligand
of the orphan receptor ST2, a member of the Toll-like/IL-1R
superfamily (Schmitz et al., 2005). It is recognized as an
alarmin or danger-associated molecular pattern because it is
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released during epithelial cell death, is associated with
infection or tissue injury, and is induced by microbial ligands
through a TLR-mediated pathway (Moussion et al., 2008).
Strong evidence demonstrates that IL-33 has an important
role in allergic diseases (Schmitz et al., 2005). First, IL-33 is
markedly elevated in the serum of patients during anaphy-
lactic shock (Pushparaj et al., 2009), in asthmatic subjects,
and in the skin of subjects with AD (Pushparaj et al., 2009;
Oboki et al., 2011). Second, IL-33 has an important role in
the early phase of the Th2 immune response to intestinal
helminths, acting as a bridge between innate and adaptive
immunity (Humphreys et al., 2008). Last, mast cells not only
produce IL-33 in response to IgE-dependent activation, but
also amplify the inflammation resulting from both IgE-
dependent and IgE-independent mast cell and basophil
activation (Hsu et al., 2010; Silver et al., 2010).
IL-25 (or IL-17E), a member of the IL-17 cytokine family,
when overexpressed in murine models results in the
production of Th2 cytokines IL-4, IL-5, and IL-13, eosinophi-
lia, and elevated serum IgE, similar to what has been
observed with TSLP and IL-33 (Fort et al., 2001). IL-25 is
expressed by mouse epithelial cells following allergen
stimulation (Angkasekwinai et al., 2007) and in the human
skin of AD patients (Wang et al., 2007). Whether barrier
disruption/tissue injury induces IL-25 production by human
keratinocytes has not been studied. However, IL-25 might
contribute to barrier dysfunction in AD subjects. It was
recently shown that IL-25 inhibits FLG synthesis by keratino-
cytes (Hvid et al., 2011), and therefore IL-25 is capable of
promoting AD, both by its effects on the adaptive immune
response and on epidermal barrier.
LC activation after barrier disruption
The skin is protected by a variety of antigen-presenting cells.
In the epidermis, LCs form a dense network that covers the
whole body. A large number of other DC subpopulations are
found in the dermis, and under inflammatory conditions
migrate into the epidermis. LCs and dermal DCs thus form
several layers of immunological defense; however, their
specific roles in skin immunity are still controversial (Merad
et al., 2008). Skin DCs take up antigens encountered in the
skin and migrate to draining lymph nodes, where they present
the antigens to T cells. Mechanical or chemical stress on the
epidermis has been reported to activate LCs, which is thought
to be mediated by the secretion of proinflammatory cytokines
from keratinocytes (Lessard et al., 1966, 1968; Streilein et al.,
1982; Wood et al., 1992; Nickoloff and Naidu, 1994;
Nishijima et al., 1997; Figure 3). Under steady-state condi-
tions, LCs are on standby with their dendrites aimed outward,
positioned close to, but never crossing, the TJ barrier (Kubo
et al., 2009), even though they express the key TJ component,
claudin-1 (Zimmerli and Hauser, 2007; Figures 1 and 2).
Once they are activated, which can occur in response to
mere tape stripping of the skin surface, LCs extend their
dendrites through TJ barriers, become activated, and take up
antigens from the extra-TJ environment (Kubo et al., 2009).
Whether the tape stripping causes transient openings of TJs,
the release of epidermal mediators that activate LCs, direct
dendrite migration to the epidermal surface, or all of the
above has yet to be determined. Interestingly, the epidermal
TJ integrity is maintained by the de novo formation of TJs
between keratinocytes and LCs, suggesting that LCs are able
to take up foreign antigens from outside TJ barriers without
penetration of the antigen through the TJ barriers (Kubo et al.,
2009). As TJs are a size-limiting barrier (Tsukita et al., 2001),
it is possible that some smaller antigens, haptens, or
chemicals may penetrate the TJ barrier and through this
mechanism encounter LCs or DCs. Thus, we need to
reevaluate each antigen and allergen individually to deter-
mine the limits of their penetration in the context of relevant
‘‘barrier-disrupted’’ conditions.
CONCLUSIONS
In this review, we have highlighted several new concepts that
demonstrate the dynamic interaction between the epidermis
and the immune system. Many of these concepts were the
direct result of early observations made by cutaneous
biologists who noted barrier defects in inflammatory skin
disorders over 100 years ago. The recognition that keratino-
cytes are not just important to maintain tissue structure,
polarity, and to provide a fence-like function but also to
respond dynamically to environmental perturbations is still a
relatively novel concept. In their role as ‘‘first responders,’’
they have clearly emerged as a key cell in the innate immune
system. We have highlighted several human skin diseases
with mutations that lead to a defective skin barrier and are
often associated with markers of a Th2 response (IgE
and eosinophilia) and have clinical features characteristic
of an atopic disorder, most commonly, AD (Table 1). It is
suspected, but not known, whether disorders characterized
by a defect in TJ would also be associated with Th2 responses
and atopic features. Interestingly, there is a monogenetic
disorder called NISCH (neonatal ichthyosis–sclerosing cho-
langitis) syndrome, which is caused by a mutation in claudin-
1, and has a skin phenotype notable for ichthyosis, as the
name implies, and pruritus. Unfortunately, we do not know
whether these subjects have a skin barrier defect and whether
they have greater allergen sensitization or atopic diseases. A
number of genetically altered mouse models have highlighted
the complex network of proteins that are important for a
healthy skin barrier (Table 2). When this barrier is disrupted
by mechanical means or genetically altered as in the case of
the complete absence of FLG (ft/ft mice), the epidermis
becomes permissive to allergen sensitization. The adaptive
immune response that predominates when the skin barrier is
physically disrupted is Th2 polarized, whereas in the ft/ft
mouse a mixture of Th responses (Th1, Th2, and Th17) is
observed. This finding, coupled with the evidence that the
enhanced epidermal water loss (e.g., m TEWL) characteristic
of AD patients with moderate to severe disease is not fully
explained by FLG mutations, suggests that these mutations
may not be the sole barrier defect in this disease. Many other
abnormalities have been found in AD subjects that could
affect barrier and include defects in lipid metabolism, altered
expression of antimicrobial peptides, dysregulated EDC
genes, altered activity of endogenous proteases, reduced
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activity of endogenous antiproteases, TJ defects, and simple
trauma from the persistent itch–scratch cycle. Some of these
defects are likely genetic (FLG, SPINK5), whereas others may
be acquired (e.g., trauma from scratching, in response to the
actions of Th2 and Th17 cytokines or on an epigenetic basis).
The mechanism(s) by which epidermal barrier disruption
informs and directs the adaptive immune response to antigens
is becoming clearer. We have presented the data that
implicate several epidermal-derived cytokines (TSLP, IL-25,
and IL-33) in directing a Th2 immune response and would
likely be operative when the barrier is compromised. In
addition, transient compromise in skin barrier provides the
signals that lead to movement of LC dendrites through TJ and
ultimately the engulfment of antigens present on the
epidermal surface. We have not discussed the various subsets
of skin-resident DCs or their relative effects on the adaptive
immune system, as this remains a highly controversial area.
In conclusion, although we have summarized important
evidence suggesting that skin barrier impairment appears to
be an important determinant of allergen sensitization, we did
not conclusively answer our initial question, ‘‘Is skin barrier
disruption a requisite for allergen sensitization?’’ Sorting out
the relative importance of specific epidermal barrier defects
and the pathways by which they affect immune functions will
be the charge for cutaneous biologists over the next 75 years.
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